Please provide your email address to receive an email when new articles are posted on . Adopting respiratory viral panel testing led to shorter antibiotic usage and a lower risk for C. difficile ...
FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) ...
Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel. The Panel detects 21 clinically-relevant viral and bacterial ...
BIRMINGHAM, Ala., Oct. 2, 2025 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays, today announced it has submitted a 510(k) premarket notification ...
Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) ...
Streamlining Respiratory Virus Testing with Molecular Diagnostics: Impact on patients and laboratory
Join us for an insightful webinar on the critical role of molecular diagnostic testing for respiratory viruses during flu season. This session will explore the importance of accurate and timely ...
QIAGEN N.V. QGEN recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback